Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S due to alleged securities fraud affecting investors between November 2, 2022, and December 19, 2024 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors impacted by the company's underperformance in the "REDEFINE 1" trial, which reported a weight loss of 22.7% after 68 weeks, falling short of the expected 25% [2] - Following the announcement of the trial results, Novo's stock price dropped by $18.44, closing at $85.00 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]